Ospray Captan WG Fungicide

Hazard statements

This product is classified as: Xi, Irritating. T, Toxic. N, Dangerous to the environment. Hazardous according to the criteria of SWA. Not subject to the ADG Code when transported by Road or Rail in containers up to 500kg. (ADG 7, Special Provision AU01). R23, R40, R41, R43, R50. Toxic by inhalation. Limited evidence of a carcinogenic effect. Risk of serious damage to eyes. May cause sensitisation by skin contact. Very toxic to aquatic organisms.

Precautionary statements

S26, S28, S38, S45, S61, S1/2, S36/37/39. In case of contact with eyes, rinse immediately with plenty of water and contact a doctor or Poisons Information Centre. After contact with skin, wash immediately with plenty of soap and water. In case of insufficient ventilation, wear suitable respiratory equipment. In case of accident or if you feel unwell, contact a doctor or Poisons Information Centre immediately (show this MSDS where possible). Avoid release to the environment. Refer to special instructions/Safety Data Sheets. Keep locked up and out of reach of children. Wear suitable protective clothing, gloves and eye/face protection.

SUSDP Classification

S6

ADG classification

Class 9 Miscellaneous dangerous goods

UN Number

3077, ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S Emergency Overview Physical Description & Colour: Grey-brown granulated solid. Odour: No data.

Health hazards

The rat oral LD50 for Captan ranges from 8400 to 15,000 mg/kg, indicating very low acute toxicity. The mouse LD50 is 7000 mg/kg. Sheep showed no effect at doses of 200 mg/kg, but experienced deaths at 250 mg/kg. The inhalation LC50 (2-hour) in mice is 5.0 mg/L. Rabbits showed little or no skin sensitization to Captan, while guinea pigs were moderately sensitive. Workers exposed to high concentrations of Captan in air (6 mg/m3) experienced eye irritation including burning, itching, and tearing. Skin irritation also occurred in some cases. This product is toxic if inhaled, there is a limited evidence of a carcinogenic effect, may cause serious damage to eyes, possible skin sensitiser.

Potential health effects

Inhalation: Short Term Exposure: Available data shows that this product is toxic, but symptoms are not available. In addition product may be mildly irritating, although unlikely to cause anything more than mild transient discomfort. Long Term Exposure: No data for health effects associated with long term inhalation. Skin Contact: Short Term Exposure: Classified as a potential sensitiser by skin contact. Exposure to a skin sensitiser, once sensitisation has occurred, may manifest itself as skin rash or inflammation, and in some individuals this reaction can be severe. In addition product may be irritating, but is unlikely to cause anything more than mild transient discomfort. Long Term Exposure: No data for health effects associated with long term skin exposure. Eye Contact: Short Term Exposure: This product is a severe eye irritant. Symptoms may include stinging and reddening of eyes and watering which may become copious. Other symptoms such as swelling of eyelids and blurred vision may also become evident. If exposure is brief, symptoms should disappear once exposure has ceased. However, lengthy exposure or delayed treatment is likely to cause permanent damage. Long Term Exposure: No data for health effects associated with long term eye exposure. Ingestion: Short Term Exposure: Significant oral exposure is considered to be unlikely. However, this product may be irritating to mucous membranes but is unlikely to cause anything more than transient discomfort. Long Term Exposure: No data for health effects associated with long term ingestion. Carcinogen Status: SWA: Captan is classified by SWA as a Class 3 Carcinogen, possibly carcinogenic to humans. See the SWA website for further details. A web address has not been provided as addresses frequently change. NTP: No significant ingredient is classified as carcinogenic by NTP. IARC: Captan is Class 3 - unclassifiable as to carcinogenicity to humans. See the IARC website for further details. A web address has not been provided as addresses frequently change.